BURLINGTON, Mass., Sept. 7. 2017 /PRNewswire/ -- Decision Resources Group finds that the launch of novel biologic therapies targeting nerve growth factor (NGF) will be the main driver of growth in the osteoarthritic pain market following these agents' launch, beginning in 2020, across the major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, Japan). Given the widely generic current market and the anticipated high price of these agents, their use will be reserved for later line in a small percentage of patients who are not surgical candidates or who prefer to delay surgery. Nevertheless, the sizeable osteoarthritic pain population and expected high prices of the anti-NGF therapies will drive overall major-market sales of nearly $23.5 billion in 2026.
For more information on purchasing this report, please visit our website:
Other key findings from the Disease Landscape and Forecast report entitled Osteoarthritic Pain:
- Anti-NGF therapies from Pfizer/Eli Lilly and Regeneron/Teva/Mitsubishi Tanabe Pharma will account for nearly three-quarters of major-market osteoarthritic pain sales in 2026. Current market-leading classes of opioid analgesics and NSAIDs will maintain the majority of patient share and consistent sales through 2026.
- Sales within the opioid analgesics class continue to be driven by branded abuse-deterrent formulations (ADFs), reflecting efforts to curb prescription opioid abuse. However, the cost, perceived effectiveness, and continued risk of dependence with these agents limit future growth opportunities. Grϋnenthal/Depomed's cebranopadol, with its anticipated lower abuse risk, will propel sales of the class after its launch in 2022.
- NSAIDs remain the most prescribed agents for osteoarthritic pain due to the variety and extensive generic availability in this class. Side effects associated with chronic use are a lingering concern for prescribers, and while nonoral formulations seek to resolve these concerns, development in this class has diminished from market saturation. Sales of the NSAIDs class will remain constant through 2022 before decreasing.
- The prevalence of osteoarthritic pain will continue to increase through 2026 due to an aging population and rising obesity rates.
Comments from Decision Resources Group Analyst Joyce Spadafora, ALM:
- "We expect the anti-NGF monoclonal antibodies will be the most commercially successful novel drug class for the treatment of osteoarthritic pain. While safety risks continue to shadow their perception among interviewed physicians, large ongoing Phase III safety trials may ameliorate lingering concerns. Their impressive efficacy demonstrated to date and anticipated premium pricing, together with the current absence of totally effective and safe analgesics and the large osteoarthritic pain patient population, will yield blockbuster major-market sales by 2026."
- "Opioid analgesics will remain a key player in the treatment of osteoarthritic pain. Despite increasing safety and abuse concerns associated with this class, the presence of ADFs of long-acting opioid analgesics in the United States and the anticipated improved safety profile of cebranopadol will prevent erosion of class sales over the forecast period."
- Joyce Spadafora has written a blog on the subject, which can be found here: http://bit.ly/2gphILN
About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.
Decision Resources Group
SOURCE Decision Resources Group